Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
Did you know?
What made us buy IEX@193, Tata Power@56, Titan@330, Divis@629, Persistent@700.
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Strides Pharma Science Ltd Stock Analysis

Small Cap
Evaluated by 2767 users | BSE: 532531 | NSE: STAR |
Pharmaceuticals & Drugs

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Dec'10Dec'11Dec'12Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Capital Employed 4.68%5.61%8.53%21.65%9.19%6.55%2.06%21.86%3.99%4.36%2.49%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 5057507128519292,2221,3821,9551,5371,6921,8582,138
Y-o-Y Gr. Rt.-48.5%-5%19.5%9.2%139%-37.8%41.5%-21.4%10.1%9.8%-
Adjusted EPS (Rs.) 6.9213.9122.4149.8626.6716.085.3698.7213.2414.456.227.33
Y-o-Y Gr. Rt.-101%61.1%122.5%-46.5%-39.7%-66.7%1741.8%-86.6%9.1%-57%-
Book Value per Share (Rs.) 243.14232.35232.62219.01247.18352.77360.5352.29362.84352.04361.65359.65
Adjusted Net Profit 4081.213229715914447.988411912955.866
Net Op. Cash Flow (Rs. Cr.) 48.110211.1-2.720783.141265.640138283-
Debt to Cash Flow from Ops 25.828.856.95-141.261.9518.593.919.2420.256.193.11-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Strides Pharma Science Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  10 yrs 5 yrs 3 yrs 1 yr
Net Sales 10.6%-3.5%-1.7%9.8%
Adjusted EPS -8.6%-17.3%-60.2%-57%
Book Value per Share 50.50.92.7
Share Price 1.1% -15.6% 1.2% -46%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Dec'10Dec'11Dec'12Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Equity (%) 3.435.879.6524.7310.236.21.527.633.694.031.742.03
Operating Profit Margin (%) 14.5520.3219.61714.4112.148.17.369.8213.098.579.23
Net Profit Margin (%) 7.9210.8318.5134.917.096.473.4745.187.717.6533.08
Debt to Equity 0.890.660.460.290.270.490.50.190.250.270.270.04
Working Capital Days 861933726464783293405295383333340301
Cash Conversion Cycle 403979759157123399310713235
Loading price chart...
Entity Percentage Holding
Promoters 29.60%
Institutions 45.40%
Non-Institutions 25.00%
Pledged *13.0251.2948.2050.9346.8437.0440.3832.5626.0226.02
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Strides Pharma Science Ltd's earnings have declined by -17.3%, whereas share price has declined -15.6% CAGR over the past five years, indicating the company’s share price is likely overvalued. However, for specific investment actions please consult your investment advisor.

Strides Pharma Science Ltd share price has appreciated 1.1% annually (CAGR) over the past ten years.

Data is not available for this company.

Strides Pharma Science Limited, incorporated in 1990, is a global pharmaceutical company headquartered in Bangalore, India. The Company has two business verticals, viz., Regulated Markets and Emerging Markets. Strides has a global manufacturing footprint with eight manufacturing facilities spread across four continents, including five US FDA approved facilities and two facilities for the rest of world markets. The Company has a dedicated R&D facility

Strides Pharma Science Limited, incorporated in 1990, is a global pharmaceutical company headquartered in Bangalore, India. The Company has two business verticals, viz., Regulated Markets and Emerging Markets. Strides has a global manufacturing footprint with eight manufacturing facilities spread across four continents, including five US FDA approved facilities and two facilities for the rest of world markets. The Company has a dedicated R&D facility in India with global filing capabilities and a strong footprint across many countries.

Business area of the company

The company’s core competence is in the development and manufacture of wide range of niche and technically complex pharmaceutical products. The company is also among the world's largest soft gelatin capsule manufacturers.

Products

Soft gel capsules - The company manufactures range of soft gel in category of nutraceuticals, Rx, specialty OTCs and immunosuppressants.

Steriles- Under this, it offers its products in therapeutic segments that includes beta-lactams and cephalosporins. The company manufactures striles in various forms such as prefill syringes, ampoules, vials and penicillins.

Awards

2017-18

  • Received several customer award including the Cardinal Health Supply Chain Excellence Award for 2017

2019-20

  • The Global Presence Award
  • Foreign owned business Award

Milestones

2013

  • Strides Arcolab receives ANDA approval from USFDA for Tenofovir Disoproxil Fumarate and Emtricitabine Tablet.
  • Strides Arcolab announces US FDA approval for its Italian Semi-solids and Oinment facility.
  • Strides announces WHO pre-qualification for Artemether + Lumifantrine -StelisBiopharma and Pieris Forge Alliance for Novel Anticalin Therapeutics in Ophthalmology.
  • Strides Arcolab - Re-branding Biotech Business as ''Stelis''.
  • Strides Arcolab - Pfenex Inc. and Agila Biotech Private Ltd Announce Joint Venture to Develop Biosimilar Products for the Global Market.

2014

  • Medicines for Malaria Venture announces collaborations with Cipla and Strides.
  • Strides Arcolab makes strategic investment in Oncobiologics Inc., USA.
  • Strides partners with Gilead Sciences Inc, to bring Hepatitis C cure to 91 developing countries.
  • Strides Arcolab receives US FDA approval for Buspirone Tablets.
  • Strides Arcolab receives US FDA approval for Calcitriol Softgel.
  • Strides Arcolab acquires 'Raricap' and India Branded Generic Business of Bafna.
  • Strides Arcolab to acquire Shasun Pharma in all stock deal.

2015

  • Strides Arcolab Ltd. has entered into an agreement with Fortuna Public Relations Pvt. Ltd., Delhi appointing them as Company's Public Relations Agenc
  • Strides Arcolab Ltd that it has entered into a licensing agreement with Gilead Sciences Inc,
  • Strides Arcolab Ltd has launched the generic drug Sofosbuvir in India ''Virso''
  • Strides Arcolab gets USFDA nod for Polyethylene Glycol 3350 -Strides Arcolab gets USFDA nod for HIV treatment drug
  • Strides Arcolab Ltd has approved the merger of Shasun Pharmaceuticals Ltd with the company.
  • Strides Arcolab has completed the Rs 1,910-crore acquisition of Aspen Pharmacare, Australia.
  • Strides Arcolab acquires CNS divisions of erstwhile Ranbaxy
  • Strides Arcolab Ltd has changed from its present name ''Strides Arcolab Limited'' to Strides Shasun Limited

2016

  • Strides Shasun updates on ''Acquisition of seven brands from Johnson & Johnson''.
  • Strides Shasun update on ''Acquisition of CNS divisions of erstwhile Ranbaxy''. -''Strides Shasun to acquire a strategic stake in Generic Partners Holdings, Australia.
  • Strides Shasun to acquire controlling stake in Universal Corporation, Kenya.
  • Strides Shasun receives USFDA Tentative Approval for Efavirenz Tablet.
  • Strides Shasun announces successful completion of US FDA inspection at its Oral Dosage Facility in Bangalore.

2017-18

  • Launched consumer health division in a difficult market environment.
  • Product filing and approval gained momentum with 12 new ANDA filings and 14 product approvals received
  • Witnessed single-digit price erosion for front-end portfolio 

2018-19

  • Re-launched erstwhile partnership molecules through front-end business witnessing encouraging traction which contributed to a sequential ramp-up in the US business.
  • Completed acquisition of Vensun Pharmaceuticals and took 100% ownership in a joint venture with Vivimed Labs adding ~US$ 25 million additional sales and a combined portfolio of 100+ ANDAs.
  • Entered into a strategic partnership with SUDA Pharmaceuticals for an exclusive agreement for novel and a fast-acting oral spray of sumatriptan in the US market.

2019-20

  • Increased production capacity up to 1.4 Billion tablets annually on single shift operations, with new equipment-like continuous coater, high speed automatic inspection machine-and technology - for manufacturing hot molten liquid fill into a hard gelatin capsule
  • Successfully transferred eight products of which three are approved by the US FDA; the remaining five products are expected to receive US FDA approval within the next six months.
  • Implemented Manufacturing Execution System (MES) in processing facility, with integrated electronic batch record.
  • Installed packaging serialization and automated materials tracking system (GEM-MT).
  • Equipped the unit with laser-based, high-end inspection system for scanning tablets and capsules with 3D cameras, which can identify defects as low as 20 microns leading to a high level of automated quality controls.
  • Launched two products from the Singapore unit under the procurements administered by the Department of Veteran Affairs (VA) in the US, based on its eligibility as a designated country.
  • Initiated transfer of eight new products to be manufactured in the Singapore unit.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback